ARTICLE | Clinical News
AVR118: Phase II started
October 8, 2007 7:00 AM UTC
ADVR began an open-label, Canadian Phase II trial in 14 cancer patients to evaluate 4 ml doses of subcutaneous AVR118 given once daily for 28 days. Pending preliminary data from this first cohort, up ...